-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 9, Sino-US Huadong Pharmaceutical, a wholly-owned subsidiary of Huadong Medicine, and AKSO Biopharmaceutical announced a strategic cooperation
.
According to the agreement, Sino-US Huadong Pharmaceutical will obtain the exclusive clinical development and commercialization rights in the Asia-Pacific region (excluding Japan) of the research-in-progress AB002 (for solid tumor treatment) developed by the latter.
AB002 is a dual-target fusion protein developed by AKSO, which includes a soluble PD-1 and an IL-15 agonist, which can capture PD-L1 and PD-L2 with ultra-high binding affinity, while activating IL-15.
targeted delivery of agents to tumor cells
.
The press release noted that AB002's ability to precisely target tumor cells not only avoided the activation of natural killer cells (NK cells) throughout the body, but also extended the half-life of IL-15 agonists
According to the cooperation agreement, Huadong Medicine will be responsible for the clinical development, registration and commercialization of AB002 in the Asia-Pacific region (excluding Japan), and will jointly guide the clinical trial application work with AKSO through the Joint Research Committee
.
AKSO will continue to be responsible for the development of AB002 in the rest of the world
(Original abridged)
